Peroxidase activation of 4-hydroxytamoxifen to free radicals detected by EPR spectroscopy

Free Radical Biology and Medicine

Volumn 22, Issue 3, 1997, Pages 423-431

  Davies, Adrian M ^a   Malone, Mark E ^b   Martin, Elizabeth A ^a   Jones, Russell M ^a   Jukes, Rebekah ^a   Lim, Chang Kee ^a   Smith, Lewis L ^a   White, Ian N H ^a  

^a MRC TOXICOLOGY UNIT   (United Kingdom)

^b Hodgkin Building ^*  (United Kingdom)

Author keywords

4 hydroxytamoxifen; 4 hydroxytoremifene; DNA damage; Free radical; Glutathione; Peroxidase; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; 4 HYDROXYTOREMIFENE; DROLOXIFENE; FREE RADICAL; GLUTATHIONE; HORSERADISH PEROXIDASE; HYDROGEN PEROXIDE; PHOSPHORUS 32; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMICAL CARCINOGENESIS; DNA DAMAGE; DRUG METABOLISM; DRUG SYNTHESIS; ENDOMETRIUM CANCER; ENZYME ACTIVATION; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING;

DNA ADDUCTS; ELECTRON SPIN RESONANCE SPECTROSCOPY; FREE RADICALS; GLUTATHIONE; GLUTATHIONE DISULFIDE; HORSERADISH PEROXIDASE; HYDROGEN PEROXIDE; MACROMOLECULAR SUBSTANCES; OXIDATION-REDUCTION; PHOSPHORUS RADIOISOTOPES; SPIN LABELS; TAMOXIFEN;

EID: 0031024231     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(96)00345-0     Document Type: Article

References (32)

1. Fisher B., Costantino J. P., Redmond C. K., Fisher E. R., Wickerham D. L., Cronin W. M., NSABP Contributors. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 86:1994;527-537.
2. Rutqvist L. E., Johansson H., Signomklao T., Johansson U., Fornander T., Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst. 87:1995;645-651.
3. Jordan V. C. Tamoxifen and tumorigenicity: A predictable concern. J Natl Cancer Inst. 87:1995;623-626.
4. Greaves P., Goonetilleke R., Nunn G., Topham J., Orton T. Two-year carcinogenicity study of tamoxifen in Alderly Park Wistar-derived rats. Cancer Res. 53:1993;3919-3924.
5. Hard G. C., Iatropoulos M. J., Jordan K., Radi L., Kaltenberg O. P., Imondi A. R., Williams G. M. Major differences in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Cr1: CD(BR) rats. Cancer Res. 53:1993;4534-4541.
6. 32P-postlabelling in three rat stains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumour formation. Carcinogenesis. 16:1995;1299-1304.
7. Mani C., Kupfer D. Cytochrome P450 mediated action and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of the flavin-containing monooxygenases in tamoxifen activation. Cancer Res. 51:1991;6052-6058.
8. 14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochem Pharmacol. 49:1995;1035-1042.
9. White I. N. H., De Matteis F., Davies A., Smith L. L., Crofton Sleigh C., Venitt S., Hewer A., Phillips D. H. Genotoxic potential of tamoxifen and analogues in female Fischer F344/N rats, DBA/2 and C57Bl/6 mice and in human MCL-5 cells. Carcinogenesis. 13:1992;2197-2203.
10. Dahme E., Rattel B. Unlike tamoxifen, droloxifene produces no hepatic tumors in the rat. Onkologie. 17:1994;6-16.
11. Wiseman H., Halliwell B. Carcinogenic antioxidants, diethylstilboestrol, hexoestrol and 17 alpha-ethynyloestradiol. Febs Letters. 332:1993;159-163.
12. Davies A. M., Martin E. A., Jones R. M., Lim C. K., Smith L. L., White I. N. H. Peroxidase activation of tamoxifen and toremifene to cause DNA damage and covalently bound protein adducts. Carcinogenesis. 16:1995;539-545.
13. Pathak D. N., Pongracz K., Bodell W. J. Microsomal and peroxidase activation of 4-hydroxytamoxifen to form DNA adducts: comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen. Carcinogenesis. 16:1995;11-15.
14. 32P-Postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis. 16:1995;1651-1654.
15. Lien E. A., Solheim E., Lea O. A., Lundgren S., Kvinnsland S., Ueland P. M. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 49:1989;2175-2183.
16. McCague R. The use of perfluorotolyl protecting groups in the synthesis of pure Z and E isomers of 4-hydroxytamoxifen (1-(4-(2-dimethylaminoethoxy)phenyl-1-(4-hydroxyphenyl)-2-phenyl-1-butene. J Chem Res. (M). 1986;771-793.
17. Lim C. K., Yuan Z., Lamb J. H., White I. N. H., De Matteis F., Smith L. L. A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis. 15:1994;589-593.
18. Pathak D. N., Bodell W. J. DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis. 15:1994;529-532.
19. Jones R. M., Yuan Z., Lamb J. H., Lim C. K. On-line high-performance liquid chromatographic-electrospray ionization mass spectrometric method for the study of tamoixfen metabolism. J. Chromatog. A. 722:1995;249-255.
20. Martin J., White I. N. H. Fluorimetric determination of oxidised and reduced glutathione in cell and tissues by high performance liquid chromatography following derivatization with dansyl chloride. J. Chromatog. 568:1991;219-225.
21. Holinka C. F., Gurpide E. Peroxidase activity in glands and stroma of human endometrium. Am J. Obstet. Gynecol. 138:1980;599-603.
22. Ross D., Mehlhorn R. J., Moldeus P., Smith M. T. Metabolism of diethylstilbestrol by horseradish peroxidase and prostaglandin-H synthase. J. Biol Chem. 260:1985;16210-16214.
23. Sipe H. J., Jordan S. J., Hanna P. M., Mason R. P. The metabolism of 17b-estradiol by lactoperoxidase: a possible source of oxidative stress. Carcinogenesis. 15:1994;2637-2643.
24. Schreiber J., Fourman G. L., Hughes M. F., Mason R. P., Eiling T. E. Detection of glutathione thiyl free radical catalyzed by prostaglandin H synthase present in keratinocytes. J Biol Chem. 264:1989;7936-7943.
25. Rao D. N. R., Fischer V., Mason R. P. Glutathione and ascorbate reduction of the actaminophen radical formed by peroxidase. J Biol Chem. 265:1996;844-847.
26. Snyder R., Witz G., Goldstein B. D. The toxicology of benzene. Environmental Health Perspectives. 100:1993;293-306.
27. Potter D. W., Miller D. W., Hinson J. A. Horseradish peroxidase-catalysed oxidation of acetaminophen to intermediates that form polymers or conjugates with glutathione. Mol. Pharmacol. 29:1986;155-162.
28. Osborne M. R., Hewer A., Hardcastle I. R., Carmichael P. L., Phillips D. H. Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res. 56:1996;66-71.
29. Moorthy B., Sriram P., Pathak D. N., Bodell W. J., Randerath K. Tamoxifen metabolic activation: Comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo. Cancer Res. 56:1996;53-57.
30. 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis. 15:1994;2089-2094.
31. Lien E. A., Solheim E., Ueland P. M. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res. 51:1991;4837-4844.
32. Pujol H., Girault J., Rouanet P., Fournier S., Grenier J., Simony J., Fourtillan J. B., Pujol J. L. Phase I study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue. Cancer Chemotherapy and Pharmacology. 36:1995;493-498.